| Literature DB >> 31137691 |
Aleksandra Wesolowska1, Elena Sinkiewicz-Darol2, Olga Barbarska3, Urszula Bernatowicz-Lojko4, Maria Katarzyna Borszewska-Kornacka5, Johannes B van Goudoever6.
Abstract
Human milk not only contains all nutritional elements that an infant requires, but is also the source of components whose regulatory role was confirmed by demonstrating health-related deficiencies in formula-fed children. A human milk diet is especially important for premature babies in the neonatal intensive care unit (NICU). In cases where breastfeeding is not possible and the mother's own milk is insufficient in volume, the most preferred food is pasteurized donor milk. The number of human milk banks has increased recently but their technical infrastructure is continuously developing. Heat treatment at a low temperature and long time, also known as holder pasteurization (62.5 °C, 30 min), is the most widespread method of human milk processing, whose effects on the quality of donor milk is well documented. Holder pasteurization destroys vegetative forms of bacteria and most viruses including human immunodeficiency virus (HIV) herpes and cytomegalovirus (CMV). The macronutrients remain relatively intact but various beneficial components are destroyed completely or compromised. Enzymes and immune cells are the most heat sensitive elements. The bactericidal capacity of heat-pasteurized milk is lower than that of untreated milk. The aim of the study was for a comprehensive comparison of currently tested methods of improving the preservation stage. Innovative techniques of milk processing should minimize the risk of milk-borne infections and preserve the bioactivity of this complex biological fluid better than the holder method. In the present paper, the most promising thermal pasteurization condition (72 °C-75 °C,) and a few non-thermal processes were discussed (high pressure processing, microwave irradiation). This narrative review presents an overview of methods of human milk preservation that have been explored to improve the safety and quality of donor milk.Entities:
Keywords: breastfeeding; donor milk; high pressure processing; holder pasteurization; human milk; newborn
Mesh:
Year: 2019 PMID: 31137691 PMCID: PMC6566440 DOI: 10.3390/nu11051169
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Studies of Holder Pasteurization, High-Temperature Short-Time, High Pressure Processing and Microwave Irradiation HoP, HTST, HPP, MI on microbiological and viral components of human milk.
| Tested Component | HoP | HTST | HPP | MI | References |
|---|---|---|---|---|---|
| Bacteriostatic effect on | 48% reduction | 64% reduction | not studied | not studied | [ |
| Inactivation of selected microorganisms | inactivation | not studied | inactivation | not studied | [ |
| Inactivation of selected microorganisms ( | inactivation | not studied | inactivation | not studied | [ |
| Inactivation of selected microorganisms ( | not studied | not studied | inactivation | not studied | [ |
| Antibacterial efficacy (Coagulase-negative staphylococci, Gram- negative bacteria, Enterococcus species) | reduced bacterial counts | reduced bacterial counts | not studied | not studied | [ |
| Microbiological quality (vegetative forms of microorganisms present in raw milk samples) | destroyed commensal and contaminant vegetative microorganisms except | destroyed all vegetative forms of microorganisms except | not studied | not studied | [ |
| Inactivation of selected microorganisms ( | inactivation | not studied | inactivation | not studied | [ |
| Inactivation of selected microorganisms ( | partial inactivation | not studied | inactivation | not studied | [ |
| Inactivation of selected microorganisms ( | inactivation | not studied | not studied | inactivation | [ |
| Ebola Virus | inactivation | not studied | not studied | not studied | [ |
| Marburg Virus | inactivation | not studied | not studied | not studied | [ |
| Zika virus | inactivation | not studied | not studied | not studied | [ |
| CMV | Inactivation | destroy viral infectivity | not studied | inactivation | [ |
| HTLV | inactivation | inactivation | not studied | not studied | [ |
| HPV high-risk (types 16 and 18), low-risk (type 6) | inactivation | not studied | not studied | not studied | [ |
HoP–Holder Pasteurization, HTST–High-Temperature Short-Time, HPP–High Pressure Processing, MI–Microwave Irradiation CMV–cytomegalovirus, HTLV–human T lymphotropic virus, HIV–human immunodeficiency virus.
Effects of different type of processing (Holder Pasteurization, High-Temperature Short-Time, High Pressure Processing and Microwave Irradiation) on human milk factors.
| Factor | HoP | HTST | HPP | MI | References |
|---|---|---|---|---|---|
| Activity Loss/Reduce of Concentration | Activity Loss/Reduce of Concentration | Activity Loss/Reduce of Concentration | Activity Loss/Reduce of CONCENTRATION | ||
| Lactoferrin | 63–100% | 11% | * decrease (600 MPa, 15 min) | ns | [ |
| Lysozyme | * decrease 21–67% (reduction concentration) | 55% | 107% | * decrease | [ |
| Antioxidant activity (glutathione, glutathione peroxidase, malonedialdehyde, superoxide dismutase, TAC) | * decrease in glutathione concentration (about 50%), GPx activity (near 67%) and TAC (about 58%) reduced GPx | Decrease | no significant changes in TAC, reduction of AsA >11% (200 MPa, −20°C) | SOD and GPx activity temporary increased during microwave heating | [ |
| Oligosaccharides | stable | Stable | ns | ns | [ |
| Biogenic amines | stable | Ns | ns | ns | [ |
| Glucocorticoids (cortisol, cortisone) | not significantly affected | [ | |||
| Adiponectin | 34% | Ns | 62–98% | ns | [ |
| Insulin | 46% | Ns | 5–18% | ns | [ |
| Leptin | 40% (57 °C, 30 min) | Ns | 48–90% (* increase in leptin concentration) | ns | [ |
| Medium-chain saturated fatty acids | no change in content | Ns | no change in content | ns | [ |
| Long-chain unsaturated fatty acids | no change in content, slight decrease of oleic acid content | Ns | no change in content |
| [ |
| Polyunsaturated | no change in content | Ns | no change in content | ns | [ |
| Folic acid | 36% | * increase | ns | ns | [ |
| Vitamin A | Stable decrease from 55.5 mg/100 mL to 36.6 mg/100 mL, about 34% | Stable | ns | ns | [ |
| Vitamin B1(thiamine) | ns | Stable | ns | ns | [ |
| Vitamin B2 | stable | stable | ns | ns | [ |
| Vitamin B6 | 15% | stable | ns | ns | [ |
| Vitamin B12 | 48% | increase | ns | ns | [ |
| Vitamin C | 36% | stable | no change | ns | [ |
| Vitamin D | stable | Ns | ns | ns | [ |
| Vitamin E (tocopherol) | stable | Ns | ns | ns | [ |
| Lysine | higher content of available lysine | Stable | ns | ns | [ |
| IgM | complete deactivation | Ns | ns | ns | [ |
| IgA | 20–100% | 20% | 0% (400 mPa) | no significant effect | [ |
| IgG | 34–100% | 33% | 18–70% | ns | [ |
| Alkaline phosphatase | complete loss | 94% | ns | ns | [ |
| Lipoprotein Lipase | complete loss | stable | 15–20% | [ | |
| Lactoperoxidase | 50–88% | stable | ns | ns | [ |
| Amylase | 15% | ns | ns | ns | [ |
| Mannose-binding lectin | stable | ns | ns | ns | [ |
| CD 14 (soluble) | 88% | ns | ns | ns | [ |
| TGF β1TGF β1 | decrease <1% | ns | stable | ns | [ |
| TGF α | decrease <6% | ns | ns | ns | [ |
| IL-10 | * decrease in content | substantial decrease | decrease (400 MPa, 5 min, 12 °C) | ns | [ |
| Erythropoietin | decrease | ns | ns | ns | [ |
| IFN- | decrease in content | ns | ns | ns | [ |
| TNF-α | * decrease in content | ns | decrease (400 MPa), | ns | [ |
| TNF-RI | increase in content | ns | increase (400 MPa), increase (500 MPa), | ns | [ |
| IL-1 α | * decrease in content | ns | ns | ns | [ |
| IL-2 | decrease in content | ns | ns | ns | [ |
| IL-4 | decrease in content | ns | ns | ns | [ |
| IL-5 | decrease in content | ns | ns | ns | [ |
| IL-12p70 | decrease in content | ns | ns | ns | [ |
| IL-13 | *decrease in content | ns | increase (400 MPa), | ns | [ |
| IL-8 | 25% increased content | not studied | increase (400 MPa), | ns | [ |
| IL-6 | * decrease of activity | ns | increase (400 MPa, 500 MPa, 600 MPa) | ns | [ |
| HGF | 33% | ns | 3–66% | ns | [ |
| EGF | stable | stable | stable | ns | [ |
| IGF-1 | 39%, | stable | ns | ns | [ |
| IGF-2 | 9.9% | stable | ns | ns | [ |
| IGF-BP2 | 19.1% | stable | ns | ns | [ |
| IGF-BP3 | 7% | stable | ns | ns | [ |
| Free nucleotide monophosphates (AMP, GMP, CMP, TMP) | stable | ns | 400, 500, 600 MPa 5 min (without temp. control) stable or increased content | ns | [ |
| Volatile profile | modified the volatile profile (lipid oxidation, Maillard reaction) | ns | HPP at 400 or 600 MPa for 3 min preserved the original volatile compounds of human milk | ns | [ |
|
| |||||
| Fatty acids, cytokines, leukocytes and immunoglobulins (IgM, IgA and IgG) | ns | ns | 300–900 MPa, temp. 50–80 °C, for 1 min | ns | [ |
|
|
|
|
|
|
|
|
|
|
|
| ||
| Tocopherols, fatty acids, cytokines (IL-6, IL-8, IL-10, IL-12 (p70), IL-17, IFN-γ, TNF-α and MCAF/MCP-1) | * decreased the levels of α-, γ-and δ-tocopherol | ns | 600 MPa * decreased the levels of α-, γ- and δ-tocopherol, reduction proportions of some key fatty acids, not affect on the levels of IL-6, IL-8 and TNF-α. | ns | [ |
| IgA, IgM, IgG, | IgA 20% | ns | no/small effect on Igs, | ns | [ |
| volatile profile | ns | ns | 300–900 MPa, 50–80 °C | ns | [ |
HoP–Holder Pasteurization, HTST–High-Temperature Short-Time, HPP–High Pressure Processing, MI–Microwave Irradiation, MPa–Megapascal, GPx–glutathione peroxidase, TAC–total antioxidant capacity, AsA–ascorbic acid, SOD–superoxide dismutase, HMV–high molecular weight, IgA–immunoglobulin A, IgM–immunoglobulin M, IgG–immunoglobulin G, CD 14–cluster of differentiation 14, TGF β–transforming growth factor beta 1, TGF β–transforming growth factor beta 2, TGF α–transforming growth factor alpha, IL10–interleukin 10, IFN-γ–interferon gamma, TNF α–tumor necrosis factor alpha, TNF-RI–tumor necrosis factor receptor, IL-1α–interleukin 1 alpha, IL-2–interleukin 2, IL-4–interleukin 4, IL-5–interleukin 5, IL-12p70–interleukin 12, IL-13–interleukin 13, IL-8–interleukin 8, IL-6–interleukin 6, IL 17–interleukin 17, HGF–hepatocyte growth factor, EGF–epidermal Growth Factor, IGF1–insulin-like growth factor, IGF2–insulin-like growth factor 2, IGF-BP2–insulin like growth factor binding protein 2, IGF-BP3–insulin like growth factor binding protein 3, AMP–adenosine monophosphate, GMP–guanosine monophosphate, CMP–cytidine monophosphate, TMP–thymidine monophosphate, MCAF/MCP-1–monocyte chemotactic and activating factor/monocyte chemoattractant protein-1,* statistically significant (p < 0,05), ns–not studied.